

Leukomed® Sorbact®

Clinically proven wound infection prevention ¹

Cost effective surgical site infection reduction ²

Safe and unique Sorbact® bacteria binding technology



Leukomed[®] Sorbact[®]

Innovative surgical post-operative dressing helps to reduce wound bioburden to colonize by its physical mode of action.

Effectiveness proven in clinical evidence:

- Clinically significant 65% relative risk reduction of acquiring a surgical site infection post caesarean section¹
- Up to 57% cost reduction of SSI when treating caesarean sections, using NHS cost model²
- Effective reduction of the bacterial burden in critically colonised or locally infected wounds³

Unique bacteria-binding Sorbact®

- Effectively binds hydrophobic bacteria and fungi
- · No development of bacterial resistance


Indications

All post-operative and traumatic wounds with dry to low exudate levels

- Surgical incisions
- Post-operative dehisced
 wounds
- Lacerations, cuts, abrasions
- Minor burns

Bacteriaproof adhesive film

- Effectively protects against external contamination
- Breathable and shower-proof



- 1) Stanirowski J, Bizon M, Cendrowski K, et al (2016b) Randomized controlled trial evaluating dialkylcarbomyl chloride impregnated dressings for the prevention of surgical site infections in adult women undergoing caesarean section. Surg Infect (Larchmt) 17(4): 427 -35
- 2) Davies H, McMaster J, et al. Cost-effectiveness of DACC dressing to prevent SSI following caesarean section. Presented at Wounds UK, Harrogate, November 2018
- 3) Cutting K, Maguire J (2015) Safe bioburden management. A clinical review of DACC technology. Journal of Wound Care Vol 24, No 5



